Table 2 Characteristics of the population according to the post 1 month IFN-γ producing NK cell proportion
Variables | All patients (n = 42) | Group 1, IFN-γ producing NK cell proportion ≥ 45% (n = 26, 61.9%) | Group 2, IFN-γ producing NK cell proportion < 45% (n = 16, 38.1%) | P value |
|---|---|---|---|---|
Age, years | 62.6 (65.5–68.3) | 62.5 (56.3–68.5) | 62.1 (55.8–68.8) | 0.889 |
Male gender | 29 (69.0) | 15 (57.7) | 13 (81.2) | 0.116 |
Etiology | 0.082 | |||
Hepatitis B virus | 25 (59.5) | 13 (50.0) | 12 (75.0) | |
Hepatitis C virus | 4 (9.5) | 4 (15.4) | 0 (0.0) | |
Alcohol | 7 (16.7) | 3 (11.5) | 4 (25.0) | |
Others | 6 (14.3) | 6 (23.1) | 0 (0.0) | |
Liver cirrhosis | 32 (76.2) | 19 (73.1) | 13 (81.2) | 0.546 |
Child–Pugh class | 0.969 | |||
A | 34 (81.0) | 21 (80.8) | 13 (81.2) | |
B | 8 (19.0) | 5 (19.2) | 3 (18.8) | |
BCLC stage | 0.897 | |||
0 | 13 (31.0) | 7 (26.9) | 6 (37.5) | |
A | 21 (50.0) | 14 (53.8) | 7 (43.8) | |
B | 8 (19.0) | 5 (19.3) | 3 (18.7) | |
Total bilirubin, mg/dL | 1.07 (0.60–1.10) | 1.15 (0.60–1.10) | 0.94 (0.40–1.65) | 0.433 |
Albumin, g/dL | 4.1 (3.7–4.5) | 4.1 (3.6–4.5) | 4.1 (3.6–4.6) | 0.796 |
Aspartate aminotransferase, IU/L | 50.0 (25.0–61.5) | 53.9 (26.8–62.3) | 40.6 (24.0–60.0) | 0.206 |
Alanine aminotransferase, IU/L | 37.1 (19.0–51.0) | 39.5 (19.0–56.8) | 28.6 (17.0–40.0) | 0.098 |
Platelet count, 109/L | 147.5 (87.5–195.0) | 145.2 (81.5–210.8) | 155.9 (89.5–183.5) | 0.598 |
Prothrombin time, INR | 1.09 (1.00–1.16) | 1.13 (1.05–1.16) | 1.06 (0.99–1.17) | 0.192 |
Alpha-fetoprotein, ng/mL | 3293.4 (3.6–72.0) | 40,702.0 (3.8–63.7) | 1003.8 (3.4–481.1) | 0.546 |
PIVKA-II, mAU/mL | 992.5 (14.0–102.0) | 621.2 (14.0–79.3) | 1678.2 (16.5–264.0) | 0.432 |
Type of treatment | 0.822 | |||
Resection | 28 (66.7) | 17 (65.4) | 11 (68.8) | |
Radiofrequency ablation | 14 (33.3) | 9 (34.6) | 5 (31.2) |